The Ministry of Health, through the Pharmacy and Poisons Board, has recommended the registration of Lenacapavir, a long-acting antiretroviral medicine for HIV pre-exposure prophylaxis (PrEP). In a statement dated Saturday, 10, 2026, Health CS Aden Duale stated that the approval covers Lenacapavir 300 mg tablets and Lenacapavir 464 mg injectable solution. “The Ministry of Health,